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Background: Limited data is available on the role of percutaneous left ventricular assist devices (pLVADs) during ablation of unstable VT.
Methods: Multicenter observational study of all consecutive pts undergoing VT ablation with either intra aortic balloon pump (IABP) or pLVAD. We 
compared the baseline characteristics, procedural variables, VT characteristics and outcomes between pts with IABP and other pLVADs.
Results: 38 pts underwent VT ablation with either IABP (n=10) or pLVAD (n=28; 9 w/Impella 2.5, 19 w/TandemHeart). Mean age = 67 years, 
92% males. Baseline variables, medications, and pre-procedural VT burden did not differ between groups. Mean procedure time, fluoroscopic time, 
radiofrequency ablation time, # of VTs induced/ablated and acute procedure success did not differ between groups. Compared to the IABP group, 
more pts in the pLVAD group could undergo entrainment and/or activation mapping (78% vs 40%; p=0.024), had more unstable VTs ablated (0.89 
vs 0.40; p=0.033), had more VTs terminated by ablation (p=0.012) and received fewer rescue shocks to terminate VT (1.89 vs 3.2; p =0.007). At 1 
year, there were no differences in the recurrence of VT or mortality between both the groups.
Conclusions: Use of pLVAD for VT ablation enables more detailed and accurate mapping and ablation of unstable VT compared to IABP without 
any difference in acute or long term success.
Table: Comparison between IABP and pLVAD during VT ablation
Clinical Variables Total (n=39) IABP (n=10) pLVAD (n=28) p value
Age in years 67.11 69.6 66.21 0.429
Male Sex (%) 35 (92) 9 (90) 26 (93) 0.774
Ischemic cardiomyopathy (%) 29 (76) 9 (90) 20 (69) 0.236
Left Ventricular Ejection Fraction (mean) 24.34 22.90 24.86 0.639
Previous VT Ablation (%) 13 (34) 3 (30) 10 (36) 0.554
Number of prior ICD shocks (mean) 14.89 15.6 14.64 0.769
Endocardial Ablation (%) 37 (97) 10 (100) 27 (96) 0.545
Epicardial Ablation (%) 6 (16) 1 (10) 5 (18) 0.559
CARTO Use (%) 34 (90) 10 (100) 24 (86) 0.206
Number of VTs induced 3.68 3.80 3.64 0.797
Number of VTs ablated 2.63 2.2 2.79 0.178
Entrainment/Activation Mapping (%) 26 (68) 4 (40) 22 (78) 0.024
Number of Unstable VTs Ablated 0.76 0.40 0.89 0.033
RF termination of VT per patient 1.76 1.1 2.00 0.012
External DCCV shocks per patient 2.24 3.2 1.89 0.007
Complications (%) 13 (34) 2 (20) 11 (39) 0.270
Death during follow up (%) 27 (70) 7 (70) 20 (71) 0.932
